Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (6073)	4/2/2002 3:26:24 PM
From: Tomato	Read Replies (1) \| Respond to of 52153

Peter, I've got a stupid question for you that I realize probably doesn't have a realistic answer, depends on many factors like market capitalization, size of the market for the prospective drug, percentage of ownership, etc. etc., but I'll ask it anyway: Are there any ballpark figures for the percentage change to expect in a biotech company's stock price when a key drug it has goes from Ph. I to Ph.II? From Ph. II to Ph. III? From Ph. III to approval? I guess I'd have you assume that the company currently has no approved drugs and has been burning cash. If this is totally ridiculous, ignore it. Wayne